Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma
- Status
- UNKNOWN
- Phase
- NA
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
- Status
- SUSPENDED
- Phase
- PHASE1
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
- Status
- TERMINATED
- Phase
- NA
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
- Status
- COMPLETED
- Phase
- PHASE2
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
- Status
- WITHDRAWN
- Phase
- PHASE1
First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
- Status
- UNKNOWN
- Phase
- N/A
A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
FL-101 in Surgically Resectable Non-Small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2